Myriad Defends Cancer Gene Patents To Supreme Court

Law360, New York (March 11, 2013, 5:33 PM EDT) -- Myriad Genetics Inc. urged the U.S. Supreme Court on Thursday to reject a challenge to the validity of its patents on breast cancer genes, saying that isolated genes are clearly patent-eligible because they have important uses not found in naturally occurring DNA.

While the American Civil Liberties Union, which is representing doctors challenging Myriad's patents, argues that the isolated genes are products of nature that cannot be patented, Myriad said in its brief ahead of arguments set for April 15 that its genes are the result...
To view the full article, register now.